| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Fepixnebart | LY-3016859 | Phase 2 Clinical | Eli Lilly And Company | Diabetic Neuropathies; Osteoarthritis, Knee; Diabetic Nephropathies; Osteoarthritis; Low Back Pain | Details |